Cowen resumed coverage of 908 Devices with a rating of Outperform
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 2/7/2023 | $14.00 | Overweight | Stephens |
| 3/8/2022 | $40.00 → $30.00 | Outperform | SVB Leerink |
| 10/15/2021 | Outperform | Cowen |
4 - 908 Devices Inc. (0001555279) (Issuer)
3 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
Smart Spectral Processing seamlessly integrates FTIR and Raman technologies into a single, intuitive workflow 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the launch of VipIR, a 3-in-1 handheld analyzer that sets a new standard for rapid and confident field-based chemical identification of unknown bulk solids and liquids, such as narcotics, explosives, and toxic chemicals. VipIR enables customs and border personnel and hazardous response teams to simplify workflows and eliminate guesswork, accelerating decision making on scene. At the heart of VipIR is Smart Spectral Processing (SSP), a proprietary algorithm that actively i
Autonomous Ground Security Robots with Real-Time Gas Detection Deployed to Safeguard the World's Largest Single-Day Sporting Event Asylon, the U.S. leader in robotic security solutions, in collaboration with 908 Devices, the Indianapolis Metropolitan Police Department, and the Indianapolis Motor Speedway, returned to this year's Indianapolis 500 to deploy its gas-sniffing security robots to help increase the safety and security of those attending the largest single-day sporting event in the world. More than 300,000 people attended this year's event, and Asylon's solution provided unprecedented real-time situational awareness and detection capabilities to the emergency operations center. T
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead
8-K - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
144 - 908 Devices Inc. (0001555279) (Subject)
Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously
Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00
SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue 908 Devices Inc. (NASDAQ:MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. "We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends in
At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re
Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini
908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)